ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID

Organization Name

Inventor(s)

ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID - A simplified explanation of the abstract

This abstract first appeared for US patent application 18555226 titled 'ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID

The present invention pertains to a composite formulation for oral administration containing an active pharmaceutical ingredient (API) chosen from 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, with the API having a particle size of granules ranging from 80 μm to 300 μm in the cumulative particle size distribution.

The formulation includes an API with specific particle size characteristics for optimal oral administration.
The API can be 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a related salt.
The particle size of the API granules falls within the range of 80 μm to 300 μm.
This formulation is designed to enhance the effectiveness and bioavailability of the active pharmaceutical ingredient.
The specific particle size distribution contributes to the overall performance and efficacy of the oral medication.

Potential Applications: - Pharmaceutical industry for oral drug delivery systems - Medical field for improved treatment options - Research and development for optimizing drug formulations

Problems Solved: - Enhancing the bioavailability of active pharmaceutical ingredients - Improving the effectiveness of oral medications - Providing a more precise and targeted drug delivery system

Benefits: - Increased efficacy of oral medications - Enhanced bioavailability of active pharmaceutical ingredients - Improved patient outcomes and treatment effectiveness

Commercial Applications: Title: Advanced Oral Drug Formulation for Enhanced Efficacy This technology can be utilized in pharmaceutical companies for developing innovative oral drug formulations with improved performance and bioavailability, potentially leading to new market opportunities and enhanced patient care.

Questions about the technology: 1. How does the specific particle size distribution of the API granules impact the effectiveness of the oral medication? 2. What are the potential implications of using 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid as the active pharmaceutical ingredient in oral formulations?

Original Abstract Submitted

The present invention relates to a composite formulation for oral administration comprising an active pharmaceutical ingredient (API) selected from 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, wherein the API has a particle size of granules corresponding to 90% of the maximum particle size in the cumulative particle size distribution (D(0.9)) of 80 μm or more and 300 μm or less.